BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

710 related articles for article (PubMed ID: 18618575)

  • 21. Wilms tumor and the WT1 gene.
    Lee SB; Haber DA
    Exp Cell Res; 2001 Mar; 264(1):74-99. PubMed ID: 11237525
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Management of Wilms tumors in Drash and Frasier syndromes.
    Auber F; Jeanpierre C; Denamur E; Jaubert F; Schleiermacher G; Patte C; Cabrol S; Leverger G; Nihoul-Fékété C; Sarnacki S
    Pediatr Blood Cancer; 2009 Jan; 52(1):55-9. PubMed ID: 18816692
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Current therapy for Wilms' tumor.
    Metzger ML; Dome JS
    Oncologist; 2005; 10(10):815-26. PubMed ID: 16314292
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Wilms' tumor in adults: results of the Society of Pediatric Oncology (SIOP) 93-01/Society for Pediatric Oncology and Hematology (GPOH) Study.
    Reinhard H; Aliani S; Ruebe C; Stöckle M; Leuschner I; Graf N
    J Clin Oncol; 2004 Nov; 22(22):4500-6. PubMed ID: 15542800
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Exclusion of the Wilms tumour gene (WT1) promoter as a site of frequent mutation in Wilms tumour.
    Grubb GR; Yun K; Reeve AE; Eccles MR
    Oncogene; 1995 Apr; 10(8):1677-81. PubMed ID: 7731725
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinicopathologic correlates of loss of heterozygosity in Wilm's tumor: a preliminary analysis.
    Grundy P; Telzerow P; Moksness J; Breslow NE
    Med Pediatr Oncol; 1996 Nov; 27(5):429-33. PubMed ID: 8926924
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clonality and loss of heterozygosity of WT genes are early events in the pathogenesis of nephroblastomas.
    Guertl B; Ratschek M; Harms D; Jaenig U; Leuschner I; Poremba C; Hoefler G
    Hum Pathol; 2003 Mar; 34(3):278-81. PubMed ID: 12673563
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Topotecan distribution in an anephric infant with therapy-resistant bilateral Wilms tumor with a novel germline WT1 gene mutation.
    Lugtenberg RT; Cransberg K; Loos WJ; Wagner A; Alders M; van den Heuvel-Eibrink MM
    Cancer Chemother Pharmacol; 2008 Nov; 62(6):1039-44. PubMed ID: 18273617
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Target genes of the WNT/beta-catenin pathway in Wilms tumors.
    Zirn B; Samans B; Wittmann S; Pietsch T; Leuschner I; Graf N; Gessler M
    Genes Chromosomes Cancer; 2006 Jun; 45(6):565-74. PubMed ID: 16575872
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Familial Wilms tumor.
    Ruteshouser EC; Huff V
    Am J Med Genet C Semin Med Genet; 2004 Aug; 129C(1):29-34. PubMed ID: 15264270
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nephroblastoma (Wilms' tumor): a model system of aberrant renal development.
    Re GG; Hazen-Martin DJ; Sens DA; Garvin AJ
    Semin Diagn Pathol; 1994 May; 11(2):126-35. PubMed ID: 7809506
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bilateral Wilms tumor in a boy with severe hypospadias and cryptochidism due to a heterozygous mutation in the WT1 gene.
    Köhler B; Schumacher V; Schulte-Overberg U; Biewald W; Lennert T; l'Allemand D; Royer-Pokora B; Grüters A
    Pediatr Res; 1999 Feb; 45(2):187-90. PubMed ID: 10022588
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Wilms tumor 1 gene mutations are associated with a higher risk of recurrence in young adults with acute myeloid leukemia: a study from the Acute Leukemia French Association.
    Renneville A; Boissel N; Zurawski V; Llopis L; Biggio V; Nibourel O; Philippe N; Thomas X; Dombret H; Preudhomme C
    Cancer; 2009 Aug; 115(16):3719-27. PubMed ID: 19536888
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The role of Wilms' tumor genes.
    Hirose M
    J Med Invest; 1999 Aug; 46(3-4):130-40. PubMed ID: 10687307
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Single-nucleotide polymorphism in WT1 gene in a hyperplastic intralobar nephrogenic rest with botryoid protrusion.
    Mizuno K; Hayashi Y; Tozawa K; Iwatsuki S; Kojima Y; Kohri K
    Urology; 2010 Jul; 76(1):149-52. PubMed ID: 19914700
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Wilms tumor genetics: mutations in WT1, WTX, and CTNNB1 account for only about one-third of tumors.
    Ruteshouser EC; Robinson SM; Huff V
    Genes Chromosomes Cancer; 2008 Jun; 47(6):461-70. PubMed ID: 18311776
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Decreased E-cadherin expression correlates with higher stage of Wilms' tumors.
    Safford SD; Freemerman AJ; Langdon S; Bentley R; Goyeau D; Grundy PE; Skinner MA
    J Pediatr Surg; 2005 Feb; 40(2):341-8. PubMed ID: 15750927
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Surgical management and genotype/phenotype correlations in WT1 gene-related diseases (Drash, Frasier syndromes).
    Auber F; Lortat-Jacob S; Sarnacki S; Jaubert F; Salomon R; Thibaud E; Jeanpierre C; Nihoul-Fékété C
    J Pediatr Surg; 2003 Jan; 38(1):124-9; discussion 124-9. PubMed ID: 12592634
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Decrease in LDL receptor-related protein expression and function correlates with advanced stages of Wilms tumors.
    Desrosiers RR; Rivard ME; Grundy PE; Annabi B
    Pediatr Blood Cancer; 2006 Jan; 46(1):40-9. PubMed ID: 16106426
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Upregulation of c-MYC in WT1-mutant tumors: assessment of WT1 putative transcriptional targets using cDNA microarray expression profiling of genetically defined Wilms' tumors.
    Udtha M; Lee SJ; Alam R; Coombes K; Huff V
    Oncogene; 2003 Jun; 22(24):3821-6. PubMed ID: 12802290
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 36.